Acumen Pharmaceuticals (ABOS) Consolidated Net Income (2020 - 2026)

Acumen Pharmaceuticals' Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$21.2 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 26.86% year-over-year to -$21.2 million; the TTM figure through Mar 2026 stood at -$112.8 million (up 4.31% YoY), while the FY2025 annual figure was -$120.6 million, down 16.23% from the prior year.
• Consolidated Net Income came in at -$21.2 million for Q1 2026 at Acumen Pharmaceuticals, up from -$25.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$9.1 million in Q1 2022 to a low of -$40.8 million in Q2 2025.
• A 5-year average of -$20.0 million and a median of -$15.1 million in 2023 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income plunged 195.34% in 2022 and soared 33.68% in 2025, its largest moves.
• Acumen Pharmaceuticals' Consolidated Net Income stood at -$12.9 million in 2022, then fell by 17.58% to -$15.1 million in 2023, then tumbled by 149.02% to -$37.6 million in 2024, then jumped by 33.68% to -$25.0 million in 2025, then grew by 15.26% to -$21.2 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$21.2 million, -$25.0 million, and -$25.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison